<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112791">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02118766</url>
  </required_header>
  <id_info>
    <org_study_id>AN2728-AD-301</org_study_id>
    <nct_id>NCT02118766</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anacor Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anacor Pharmaceuticals, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and efficacy of AN2728 Topical
      Ointment, 2% in children, adolescents, and adults (ages 2 years and older) with atopic
      dermatitis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Primary Efficacy Endpoint:  Proportion of subjects achieving success in ISGA at Day 29 in the AN2728 treated group compared to the vehicle treated group</measure>
    <time_frame>Day 29</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary Safety Endpoint:   Frequency of TEAEs, SAEs, and clinically significant changes in vital signs and clinical laboratory parameters in the AN2728 treated group compared to the vehicle treated group</measure>
    <time_frame>Through 36 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with an ISGA score of Clear (0) or Almost Clear (1) at Day 29 in the AN2728 treated group compared to the vehicle treated group</measure>
    <time_frame>Day 29</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to success in ISGA in the AN2728 treated group compared to the vehicle treated group</measure>
    <time_frame>Through 29 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in signs of AD in the AN2728 treated group compared to the vehicle treated group</measure>
    <time_frame>Day 29</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to improvement in pruritus in the AN2728 treated group compared to the vehicle treated group</measure>
    <time_frame>Through 29 days</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Dermatology related QoL scores in the AN2728 treated group compared to the vehicle treated group</measure>
    <time_frame>Day 29</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Dermatitis, Atopic</condition>
  <arm_group>
    <arm_group_label>AN2728 Topical Ointment, 2%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching vehicle control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching vehicle control, applied twice daily for up to 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AN2728 Topical Ointment, 2%</intervention_name>
    <arm_group_label>AN2728 Topical Ointment, 2%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females 2 years and older

          -  Has a clinical diagnosis of AD according to the criteria of Hanifin and Rajka

          -  Has AD involvement â‰¥ 5% Treatable %BSA (excluding the scalp)

          -  Has an ISGA score of Mild (2) or Moderate (3) at Baseline/Day 1

          -  All female subjects of childbearing potential and male subjects with female partners
             must use acceptable methods of contraception from the Screening Visit continuously
             until 30 days after stopping study drug

        Exclusion Criteria:

          -  As determined by the study doctor, a medical history that may interfere with study
             objectives

          -  Unstable AD or any consistent requirement for high potency topical corticosteroids

          -  History of use of biologic therapy (including intravenous immunoglobulin)

          -  Recent or anticipated concomitant use of systemic or topical therapies that might
             alter the course of AD

          -  Recent or current participation in another research study

          -  Females who are breastfeeding, pregnant, or with plans to get pregnant during the
             participation in the study

          -  Participation in a previous AN2728 clinical trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoming Lin, RN, BSN, MS</last_name>
    <role>Study Chair</role>
    <affiliation>Anacor Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robin Blumenthal, PhD</last_name>
    <phone>650-223-8597</phone>
    <email>clinicaltrials@anacor.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anacor Investigational Site</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 17, 2014</lastchanged_date>
  <firstreceived_date>April 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atopic dermatitis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
